HAVCR2 and neoplasm: Multi-checkpoint blockade: Tumor cells often develop resistance to single-agent PD-1/PD-L1 inhibitors by upregulating alternative inhibitory receptors such as LAG-3, TIGIT, and TIM-3 (90).